
CEO maligns FDA delays over depression device treatments’ US market entry
The CEO of Flow Neuroscience has called out the US Food and Drug Administration (FDA) for market entry delays for clinically validated devices for treating depression. The UK company’s CEO pointed out that in spite of these delays, the US market is instead …